Do analysts prefer BRTX or LGVN?

Longeveron has a consensus target price of $80.00, indicating a potential upside of 1,115.81%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor BRTX or LGVN?

In the previous week, Biorestorative Therapies had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for Longeveron. Biorestorative Therapies' average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NXTC or BRTX?

NextCure presently has a consensus price target of $19.00, indicating a potential upside of 142.35%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe NextCure is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NXTC or BRTX?

In the previous week, Biorestorative Therapies had 2 more articles in the media than NextCure. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BRTX or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer BRTX or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 616.78%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer BRTX or QNTM?

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 171.19%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor BRTX or QNTM?

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 3 articles in the media. Quantum Biopharma's average media sentiment score of 0.33 beat Biorestorative Therapies' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biorestorative Therapies (BRTX) Competitors

$0.14 -0.06 (-28.76%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.15 +0.01 (+4.38%)

As of 05:54 AM Eastern

Compare

BRTX vs. LGVN, NXTC, ALVR, ALLR, and QNTM

Should you buy Biorestorative Therapies stock or one of its competitors? Biorestorative Therapies's main competitors and comparable companies include Longeveron (LGVN), NextCure (NXTC), AlloVir (ALVR), Allarity Therapeutics (ALLR), and Quantum Biopharma (QNTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biorestorative Therapies compare to Longeveron?

Biorestorative Therapies (NASDAQ:BRTX) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Longeveron has a net margin of -1,977.59% compared to Biorestorative Therapies' net margin of -3,088.27%. Longeveron's return on equity of -223.19% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Longeveron	-1,977.59%	-223.19%	-150.20%

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Biorestorative Therapies has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	10.17	-$14.24M	-$1.07	N/A
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A

In the previous week, Biorestorative Therapies had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for Longeveron. Biorestorative Therapies' average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Longeveron has a consensus target price of $80.00, indicating a potential upside of 1,115.81%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Longeveron beats Biorestorative Therapies on 9 of the 15 factors compared between the two stocks.

How does Biorestorative Therapies compare to NextCure?

NextCure (NASDAQ:NXTC) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NextCure has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. NextCure's return on equity of -154.62% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

NextCure has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

NextCure presently has a consensus price target of $19.00, indicating a potential upside of 142.35%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe NextCure is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biorestorative Therapies had 2 more articles in the media than NextCure. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biorestorative Therapies has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Biorestorative Therapies	$360K	10.17	-$14.24M	-$1.07	N/A

Summary

NextCure and Biorestorative Therapies tied by winning 7 of the 14 factors compared between the two stocks.

How does Biorestorative Therapies compare to AlloVir?

Biorestorative Therapies (NASDAQ:BRTX) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Biorestorative Therapies had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Biorestorative Therapies and 0 mentions for AlloVir. Biorestorative Therapies' average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Biorestorative Therapies has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	10.17	-$14.24M	-$1.07	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

AlloVir has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. AlloVir's return on equity of -71.03% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
AlloVir	N/A	-71.03%	-61.27%

Biorestorative Therapies has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Summary

Biorestorative Therapies beats AlloVir on 8 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Allarity Therapeutics?

Biorestorative Therapies (NASDAQ:BRTX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Allarity Therapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Allarity Therapeutics' return on equity of -152.77% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Biorestorative Therapies has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 616.78%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biorestorative Therapies had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Biorestorative Therapies and 0 mentions for Allarity Therapeutics. Biorestorative Therapies' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Allarity Therapeutics	Neutral

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allarity Therapeutics has lower revenue, but higher earnings than Biorestorative Therapies. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	10.17	-$14.24M	-$1.07	N/A
Allarity Therapeutics	$320K	71.10	-$11.23M	-$0.78	N/A

Summary

Allarity Therapeutics beats Biorestorative Therapies on 9 of the 15 factors compared between the two stocks.

How does Biorestorative Therapies compare to Quantum Biopharma?

Biorestorative Therapies (NASDAQ:BRTX) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 3 articles in the media. Quantum Biopharma's average media sentiment score of 0.33 beat Biorestorative Therapies' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biorestorative Therapies has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	10.17	-$14.24M	-$1.07	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 171.19%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biorestorative Therapies has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quantum Biopharma has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Biorestorative Therapies' return on equity of -508.42% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

Biorestorative Therapies beats Quantum Biopharma on 8 of the 14 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.14M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.13	12.66	273.29	25.25
Price / Sales	10.17	1,335.53	621.79	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	3.59	16.81	13.08	6.14
Net Income	-$14.24M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-27.83%	0.14%	0.52%	-0.31%
1 Month Performance	-31.57%	8.27%	5.63%	0.64%
1 Year Performance	-91.18%	52.60%	25.31%	14.83%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	0.8473 of 5 stars	$0.14 -28.8%	N/A	-91.7%	$5.14M	$360K	N/A	7	News Coverage Upcoming Earnings Gap Down High Trading Volume
LGVN Longeveron	1.507 of 5 stars	$0.70 +3.4%	$8.00 +1,037.5%	-19.4%	$21.68M	$1.20M	N/A	20
NXTC NextCure	2.6797 of 5 stars	$5.83 -1.4%	$19.00 +225.9%	+57.4%	$21.35M	N/A	N/A	90	News Coverage
ALVR AlloVir	N/A	$4.20 +2.4%	N/A	-2.5%	$21.18M	N/A	N/A	110
ALLR Allarity Therapeutics	1.9191 of 5 stars	$1.34 +0.8%	$10.25 +664.9%	-21.4%	$21.16M	$320K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. LGVN, NXTC, ALVR, ALLR, and QNTM

How does Biorestorative Therapies compare to Longeveron?

Summary

How does Biorestorative Therapies compare to NextCure?

Summary

How does Biorestorative Therapies compare to AlloVir?

Summary

How does Biorestorative Therapies compare to Allarity Therapeutics?

Summary

How does Biorestorative Therapies compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. LGVN, NXTC, ALVR, ALLR, and QNTM

How does Biorestorative Therapies compare to Longeveron?

Is BRTX or LGVN more profitable?

Do institutionals & insiders believe in BRTX or LGVN?

Which has more risk and volatility, BRTX or LGVN?

Which has better earnings & valuation, BRTX or LGVN?

Does the media favor BRTX or LGVN?

Do analysts prefer BRTX or LGVN?

Summary

How does Biorestorative Therapies compare to NextCure?

Do insiders & institutionals believe in NXTC or BRTX?

Is NXTC or BRTX more profitable?

Which has more risk & volatility, NXTC or BRTX?

Do analysts recommend NXTC or BRTX?

Does the media refer more to NXTC or BRTX?

Which has better earnings and valuation, NXTC or BRTX?

Summary

How does Biorestorative Therapies compare to AlloVir?

Do insiders and institutionals believe in BRTX or ALVR?

Does the media favor BRTX or ALVR?

Do analysts recommend BRTX or ALVR?

Which has better earnings and valuation, BRTX or ALVR?

Is BRTX or ALVR more profitable?

Which has more risk and volatility, BRTX or ALVR?

Summary

How does Biorestorative Therapies compare to Allarity Therapeutics?

Is BRTX or ALLR more profitable?

Which has more volatility and risk, BRTX or ALLR?

Do analysts prefer BRTX or ALLR?

Does the media favor BRTX or ALLR?

Do institutionals & insiders have more ownership in BRTX or ALLR?

Which has preferable valuation and earnings, BRTX or ALLR?

Summary

How does Biorestorative Therapies compare to Quantum Biopharma?

Does the media favor BRTX or QNTM?

Which has better valuation and earnings, BRTX or QNTM?

Do analysts prefer BRTX or QNTM?

Which has more volatility & risk, BRTX or QNTM?

Do insiders and institutionals hold more shares of BRTX or QNTM?

Is BRTX or QNTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools